Switch to
More onapp

How to use scorecard? Learn more

Zydus Lifesciences Ltd

ZYDUSLIFE
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,15,158 cr, stock is ranked 79
Moderate RiskStock is 2.11x as volatile as Nifty
1,144.4541.20 (-3.47%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹1,15,158 cr, stock is ranked 79
Moderate RiskStock is 2.11x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
29.84
PB RatioPB Ratio
5.21
Dividend YieldDiv. Yield
0.26%
Sector PESector PE
44.49
Sector PBSector PB
5.96
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

46%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Zydus Lifesciences Ltd is an India-based life sciences company. The Company has a pipeline for Biologics and Vaccines.

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Investor PresentationView older 

Sep 17, 2023

PDF
View Older Presentations

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Financial TrendFinancial statements 

202120222023202414.4517.6917.4219.862.134.491.963.86
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Press Release 
Announced OnJul 19, 2024

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 19, 2024, titled "Stock Exchange intimation on completion of USFDA inspection attransdermal manufacturing site". | Download

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 19, 2024, titled "Stock Exchange intimation on completion of USFDA inspection attransdermal manufacturing site". | Download

Press Release 
Announced OnJul 19, 2024

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 19, 2024, titled "Zydus receives final approval from USFDA for its NDA ZituvimetTM XR (sitagliptin and metformin hydrochloride) extended-release tablets". | Download

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 19, 2024, titled "Zydus receives final approval from USFDA for its NDA ZituvimetTM XR (sitagliptin and metformin hydrochloride) extended-release tablets". | Download

Cash Dividend 
Ex. DateJul 28, 2023

Final • Div/Share: ₹ 6

See all events